Western Suburbs Cancer Clinical Trials

Cancer Clinical Trials

Western Suburbs Cancer Clinical Trials

If you or someone you love is facing cancer, clinical trials may provide an alternative. Northwestern Medicine offers clinical studies right in your community for a wide variety of types and stages of cancer. These research studies are designed to test new ways to diagnose, treat and prevent cancer, as well as to manage symptoms and side effects of the disease.

Clinical trials have played an important role in the fight against cancer. They are the only scientific way to prove whether a new treatment works better than current treatments. Most of the approaches that doctors use to treat cancer today would never have become available without clinical trials.

Current Central DuPage Hospital, Delnor Hospital and Kishwaukee Hospital Cancer Clinical Trials

Currently, there are a wide variety of oncology clinical trials available through physicians on the medical staffs of Northwestern Medicine Central DuPage HospitalNorthwestern Medicine Delnor Hospital and Northwestern Medicine Kishwaukee Hospital. For ease of searching, the trials are sorted into the following categories:

  • Bladder
  • Blood, Bone & Tissue
  • Brain
  • Breast
  • Colorectal
  • Esophageal
  • Kidney
  • Liver
  • Lung
  • Pancreatic
  • Prostate
  • Women's Reproductive System
  • Other Cancers

If you find a clinical trial that interests you, talk with your physician or call 630.933.6528. TTY 711.

View Trials

Study: A study of Enfortumab Vedotin (ASG-22CE) as Monotherapy or in Combination with Other Anticancer Therapies for the Treatment of Urothelial Cancer
Clinical Trial #: SGN22E-002/EV-103
NCT Number: NCT03288545
Principal Investigator: Dr. George
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: Chemoradiotherapy with or w/o Atezolizumab in Treating Patients with Localized Muscle Invasive Bladder Cancer.
Clinical Trial #: S1806
NCT Number: NCT03775265
Principal Investigator: Dr. George

Learn more at Clinicaltrials.gov

Study: Randomized, Phase III Study of Early Intervention With Venetoclax and Obinutuzumab Versus Delayed Therapy With Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study
Clinical Trial #: S1925
NCT Number: NCT04269902
Principal Investigator: Dr. Eisner
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: A Randomized Phase III Sudy of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years or Age) with Chronic Lymphocytic Leukemia (CLL)
Clinical Trial #: A041702
NCT Number: NCT03737981
Principal Investigator: Robert Eisner, DO
Contact: Research Office 630.352.5360

Learn more at Clinicaltrials.gov


Study: A Randomized 3- Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A)in Patients ≤ 70 years old with Untreated Mantle Cell Lymphoma
Clinical Trial #: EA4181
NCT Number: NCT04115631
Principal Investigator: Robert Eisner, DO
Contact: Research Office 630.352.5360

Learn more at Clinicaltrials.gov


Study: Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
Clinical Trial #: EAA173
NCT Number: NCT03937635
Principal Investigator: Dr. Eisner
Contact: Research Office 630.352.5360

Learn more at Clinicaltrials.gov


Study: A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Clinical Trial #: S1826
NCT Number: NCT03907488
Principal Investigator: Dr. Eisner
Contact: Research Office 630.352.5360

Learn more at Clinicaltrials.gov

Study: A Phase 1-2 Dose-Escalation and Expansion Study of ST101 in Patients with Advanced Unresectable and Metastatic Solid Tumors
Clinical Trial #: SAPIENCE ST101-101
NCT#: NCT04478279
Principal Investigator: Dr. Gondi
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov2


Study: Phase II Trial Of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations
Clinical Trial #: A071401
NCT #: NCT02523014
Principal Investigator: Dr. Gondi
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov2


Study: A Phase I study of Safety and Tolerability of Acetazolamide with Temozolomide in Adults with Newly Diagnosed MGMT Promoter-Methylated Malignant Glioma
Clinical Trial #: 18-048 BrainUp
Principal Investigator: Dr. Gondi
Contact: Research Office 630.933.7820


Study: A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
Clinical Trial #: NRG-BN007
NCT #: NCT04396860
Principal Investigator: Dr. Gondi
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov2


Study: Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma
Clinical Trial #: EAF151 20-062
NCT #: NCT03115333
Principal Investigator: Dr. Gondi
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov2


Study: Phase III Trial of Salvage Stereotactic Radiosurgery (SRS) or SRS + Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for First or Second Distant Brain Relapse After Upfront SRS With Brain Metastasis Velocity >/= 4 Brain Metastases/Year
Clinical Trial #: NRG-BN009
NCT #: NCT04588246
Principal Investigator: Dr. Gondi 1
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov2


Study: Combination of Checkpoint Inhibition and IDO1 Inhibition Together With Standard Radiotherapy or Chemoradiotherapy in Newly Diagnosed Glioblastoma. A Phase 1 Clinical and Translational Trial
Clinical Trial #: NU18C02
NCT #: NCT04047706
Principal Investigator: Dr. Buerki
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov2


Study: Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy versus Conventional Photon Irradiation with Concomitant and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma.
Clinical Trial #: NRG-BN001
NCT #: NCT02179086
Principal Investigator: Vinai Gondi, MD1
Contact: Allee Rauch, Study Coordinator, 630.933.4989
Learn more at Clinicaltrials.gov2


Study: A Phase II Randomized Trial of Proton vs. Photon Therapy (IMRT) for Cognitive Preservation in Patients with IDH Mutant, Low to intermediate Grade Gliomas.
Clinical Trial #: NRG-BN005
NCT #: NCT03180502
Principal Investigator: Dr. Gondi
Contact: Allee Rauch, Study Coordinator, 630.933.4989
Learn more at Clinicaltrials.gov2


Study: A Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer
Clinical Trial #: NRG-CC003
NCT #: NCT02635009
Principal Investigator: Dr. Gondi
Contact: Allee Rauch, Study Coordinator, 630.933.4989
Learn more at Clinicaltrials.gov2


Study: Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide vs. Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Clinical Trial #: N0577 (CODEL)
NCT #: NCT00887146
Principal Investigator: Dr. Gondi
Contact: Allee Rauch, Study Coordinator, 630.933.4989
Learn more at Clinicaltrials.gov2


Study: A Phase III< Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma that Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy.
Clinical Trial #: Orbus, STELLAR Study OT-15-001
NCT #: NCT02796261
Principal Investigator: Dr. Buerki
Contact: Allee Rauch, Study Coordinator, 630.933.4989
Learn more at Clinicaltrials.gov2


Study: Molecular Analysis for Therapy Choice (MATCH) for Patients with histologically documented solid tumors and lymphomas
Clinical Trial #: EAY131
NCT #: NCT02465060
Principal Investigator: Dr. Kahn
Contact: Kelly Schaffer, Study Coordinator 630.352.5450


Study: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Clinical Trial #: S1609
NCT #: NCT02834013
Principal Investigator: Dr. George
Contact: Allee Rauch, Study Coordinator, 630.933.4989
Learn more at Clinicaltrials.gov2


Study: Serum Lactate: a potential biomarker for malignant primary brain tumors and differentiator for tumor recurrence vs. radiation necrosis
Clinical Trial #: 17-049
Principal Investigator: Dr. Khan
Contact: Kelly Schaffer, Study Coordinator 630.352.5450


Study: Nervous System Tumor Bank
Clinical Trial #: 17-048
Principal Investigator: Dr. Khan
Contact: Kelly Schaffer, Study Coordinator 630.352.5450


Study: Cerebrovascular Tumor Bank
Clinical Trial #: 17-063
Principal Investigator: Dr. Khan
Contact: Kelly Schaffer, Study Coordinator 630.352.5450


Study: Detection of altered cognition in brain disease via assessment of speech abnormalities as assessed by novel verbal linguistic analysis software.
Clinical Trial #: 18-046
Principal Investigator: Dr. Khan
Contact: Kelly Schaffer, Study Coordinator 630.352.5450


Study: Phase III Trial of Observation versus Irradiation for a Gross Totally Resected Grade II Meningioma
Clinical Trial #: NRG-BN003
NCT #: NCT03180268
Principal Investigator: Dr. Gondi
Contact: Allee Rauch, Study Coordinator, 630.933.4989
Learn more at Clinicaltrials.gov2

Study: The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib
Clinical Trial #: A011801
NCT#: NCT04457596
Principal Investigator: Dr. Ayers
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer (OVELIA): A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer.
Clinical Trial #: TOL2506 OVELIA 21-041
NCT#: NCT04906395
Principal Investigator: Dr. Ayers
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: FDG PET to Assess Therapeutic Response in Patients with Bone-dominant Metastatic Breast Cancer, FEATURE,
Clinical Trial #: EA1183 22-003
NCT#: NCT04316117
Principal Investigator: Dr. Ayers
Contact: Research Office 630.933.7820 

Learn more at Clinicaltrials.gov


Study: The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib
Clinical Trial #: A011801 22-011
NCT#: NCT04457596
Principal Investigator: Dr. Ayers
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: A large-scale multicenter phase II study evaluating the protective effect of a tissue selective estrogen complex (TSEC) in women with newly diagnosed ductal carcinoma in situ.
Clinical Trial #: NU 15B06
NCT Number: NCT02694809
Principal Investigator: Mary Ahn, MD
Contact: Research Office 630.352.5362

Learn more at Clinicaltrials.gov


Study: PRAGMATIC PHASE III RANDOMIZED TRIAL OF PROTON VS. PHOTON THERAPY FOR PATIENTS WITH NON-METASTATIC BREAST CANCER RECEIVING COMPREHENSIVE NODAL RADIATION: A RADIOTHERAPY COMPARATIVE EFFECTIVENESS (RADCOMP) CONSORTIUM TRIAL
Clinical Trial #: RTOG3510/PCORI
NCT Number: NCT02603341
Principal Investigator: Dr. Thukral
Contact: Research Office 630.352.5362

Learn more at Clinicaltrials.gov


Study: Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
Clinical Trial #: CCTG MA.39
NCT Number: NCT03488693
Principal Investigator: Dr. Thukral
Contact: Research Office 630.352.5362

Learn more at Clinicaltrials.gov

Study: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
Clinical Trial #: A021502
NCT Number: NCT02912559
Principal Investigator: Dr. Dawravoo
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)
Clinical Trial #: NRG GI005
NCT Number: NCT04068103
Principal Investigator: Dr. Chawla
Contact:Research Office 630.352.5360

Learn more at Clinicaltrials.gov

Study: Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS) Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Clinical Trial #: A021703
NCT Number: NCT04094688
Principal Investigator: Dr. Dawravoo
Contact:Research Office 630.352.5362

Learn more at Clinicaltrials.gov

Study: A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)
Clinical Trial #: EA2183
NCT#: NCT04248452
Principal Investigator: Dr. Mihalcik
Contact: Research Office 630.933.7820


Learn more at Clinicaltrials.gov

Study: Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer
Clinical Trial #: NRG GI006
NCT Number: NCT03801876
Principal Investigator: Dr. Mihalcik
Contact: Research Office 630.352.5360

Learn more at Clinicaltrials.gov

Renal

Study: (PDIGEE) PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer
Clinical Trial #: A031704
NCT Number: NCT03793166
Principal Investigator: Dr. George

Learn more at Cancer.gov

Study: A Phase III Randomized Trial of Protons Versus Photons For Hepatocellular Carcinoma
Clinical Trial #: NRG GI003
NCT Number: NCT03186898
Principal Investigator: Dr. Mohammed

Learn more at Clinicaltrials.gov


Study: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Clinical Trial #: A151216
NCT Number: NCT02194738
Principal Investigator: Dr. Ferris
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Clinical Trial #: E4512
NCT Number: NCT02201992
Principal Investigator: Dr. Ferris
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: A Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer
Clinical Trial #: NRG CC003
Principal Investigator: Vinai Gondi, MD

Learn more at Clinicaltrials.gov


Study: Phase I/II Study of Hypofractionated Proton Therapy for Stage II-III Non-Small Cell Lung Cancer.
Clinical Trial #: LUN005-12
Principal Investigator: John Chang, MD

Learn more at Clinicaltrials.gov


Study: Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC.
Clinical Trial #: Protocol RTOG1308
Principal Investigator: Vinai Gondi, MD

Learn more at Clinicaltrials.gov


Study: Durvalumab vs Placebo Following Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer Patients (PACIFIC-4)
Clinical Trial #: Pacific-4
NCT Number: NCT03833154
Principal Investigator: Dr. Stutz
Contact: Research Office 630.352.5362

Learn more at Clinicaltrials.gov

Nasal and Paranasal Sinus Squamous Cell Carcinoma

Study: Phase II Randomized Trial of Neoadjuvant Chemotherapy Followed by Surgery and Post-Operative Radiation versus Surgery and Post-Operative Radiation for Organ Preservation of T3 and T4a (and Selected T4b) Nasal and Paranasal Sinus Squamous Cell Carcinoma (NPNSCC)
Clinical Trial #: EA3163
NCT Number: NCT03493425
Principal Investigator: Dr. Eisner
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Squamous Cell Carcinoma

Study: Phase II Randomized Trial of Radiotherapy with or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) with TP53 Sequencing
Clinical Trial #: EA3132
NCT Number: NCT02734537
Principal Investigator: Dr. Eisner
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Nasopharyngeal Carcinoma

Study: Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Clinical Trial #: NRG - HN001
NCT Number: NCT02135042
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Oropharyngeal Cancer

Study: Phase II/III Randomized Trial of Intensity-Modulated Proton Beam Therapy (IMPT) versus Intensity-Modulated Photon Therapy (IMRT) for the treatment of Oropharyngeal Cancer of the Head and Neck Cancer
Clinical Trial #: MDACC 2012-0825
NCT Number: NCT01893307
Principal Investigator: Dr. Mohammed
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Colorectal Cancer

Study: Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
Clinical Trial #: A221805
NCT Number: NCT04137107
Principal Investigator: Dr. Abad
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Melanoma

Study: A Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Primary Locally Advanced, Locally Recurrent or Metastatic Desmoplastic Melanoma (DM)
Clinical Trial #: S1512
NCT Number: NCT02775851
Principal Investigator: Dr. D'Souza
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Non-Hodgkin Lymphoma

Study: Phase I/II Study to Evaluate the Safety and Efficacy of Nivolumab in Combination With R-CHOP in a Cohort of Patients With DLBCL/tFL/ High Grade B-NHL
Clinical Trial #: NU17H08
NCT Number: NCT03704714
Principal Investigator: Dr. Eisner
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Mantle Cell Lymphoma

Study: A randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
Clinical Trial #: EA4151
NCT Number: NCT03267433
Principal Investigator: Robert Eisner, DO
Contact: Research Office 630.352.5360

Learn more at Clinicaltrials.gov

Multiple Myeloma

Study: Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation
Clinical Trial #: EAA181
NCT Number: NCT04566328
Principal Investigator: Dr. Eisner
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Angiosarcoma

Study: A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects With Angiosarcoma
Clinical Trial #: A091902
NCT Number: NCT04339738
Principal Investigator: Dr. Eisner
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

NCI-MATCH: Targeted Therapy Directed By Genetic Testing In Treating Patients With Advanced Refractory Solid Tumors or Lymphomas

Study: Molecular Analysis for Therapy Choice (MATCH)
Clinical Trial #: EAY131
Principal Investigator: M. Kamran Khan, DO

Learn more at Clinicaltrials.gov

Recurrent Tumors Previously Treated with Radiation Therapy

Study: Retreatment of non-CNS solid malignancies. Treatment sites: head & neck, thorax, pelvis, abdomen, extremities.
Clinical Trial #: UPCC 23309
Principal Investigator: William Hartsell, MD

Learn more at Clinicaltrials.gov

Pediatric Proton Consortium Registry (PPCR)

Study: A multi-center registry of pediatric patients treated with proton radiation therapy.
Clinical Trial #: 12-103
Principal Investigator: William Hartsell, MD

Learn more at Clinicaltrials.gov

Rare Tumors

Study: DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors
Clinical Trial #: S1609
Principal Investigator: Christopher George, MD

Learn more at Clinicaltrials.gov

Registry

Study: Evaluation tracking project: a prospective chart review of patients treated with proton therapy.
Clinical Trial #: REG001-09
Principal Investigator: William Hartsell, MD

Learn more at Clinicaltrials.gov

Cross-disease sites

Study: Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized Management of Patients
Clinical Trial #: MTG
Principal Investigator: Dr. Abad

Brain Metastases From Non-small Cell Lung Cancer (NSCLC)

Study: Pivotal, open label, randomized study of radiosurgery with or without Tumor Treating Fields for 1-10 brain metastases from non-small cell lung cancer.
Clinical Trial #: NovoCure METIS EF-25
NCT #: NCT02831959
Principal Investigator: Dr. Gondi
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov2

Study: A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer
Clinical Trial #: A021806
NCT Number: NCT04340141
Principal Investigator: Dr. Chawla
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: A Phase II Trial of Escalated Dose Proton Radiotherapy with Elective Nodal Irradiation and Concomitant Chemotherapy for Patients with Unresectable, Borderline Resectable or Medically Inoperable Pancreatic Adenocarcinoma
Clinical Trial #: PAN009-18
NCT Number: NCT02598349
Principal Investigator: Dr. Mohammed
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: Evaluating the Response to Neoadjuvant Chemotherapy with Circulating Tumor DNA in Pancreatic Cancer
Clinical Trial #: ctDNA
NCT Number: NCT04616131
Principal Investigator: Dr. Chawla
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT)
Clinical Trial #: EA2186
NCT Number: NCT04233866
Principal Investigator: Kevin Dawravoo, MD
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: Randomized Phase II Study of Platinum and Etoposide Versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Tumors including Poorly Differentiated Neuroendocrine Carcinomas and Well-Differentiated Neuroendocrine Neoplasms
Clinical Trial #: EA2142
NCT Number: NCT02595424
Principal Investigator: Kevin Dawravoo, MD
Contact: Research Office 630.352.5360

Learn more at Clinicaltrials.gov

Study: Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs
Clinical Trial #: EA2185
NCT Number: NCT04239573
Principal Investigator: Dr. Chawla
Contact: Research Office 630.352.5361

Learn more at Clinicaltrials.gov

Study: Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging Into Salvage Treatment for Patients with Node-Positive Prostate Cancer After Radical Prostatectomy
Clinical Trial #: NRG-GU008
NCT#: NCT04134260
Principal Investigator: Dr. George
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: Parallel Phase III Randomized Trials For High Risk Prostate Cancer Evaluating De-Intensification For Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (Predict-RT*) (NCT#04513717) *Prostate RNA Expression/Decipher To Individualize Concurrent Therapy with Radiation
Clinical Trial #: NRG-GU009
NCT#: NCT04513717
Principal Investigator: Dr. Bhate
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: Phase III Study of Local or Systemic Therapy INtensification DIrected in Prostate CAncer Patients with Post-ProstaTEctomy Biochemical Recurrence (INDICATE)
Clinical Trial #: EA9181
NCT#: NCT04423211
Principal Investigator: Dr. Hartsell
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: A registry of prostate cancer patients participating in a research study to learn how genetic differences can affect patient outcomes (PROMISE)
Clinical Trial #: C19-235
NCT #: NCT04995198
Principal Investigator: Dr. George
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: A Phase III Double-Blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Characterized by PTEN deficiency (CAPItello-281)
NCT #: NCT04493853
Principal Investigator: Dr. George
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer
Clinical Trial #: COMPPARE
NCT #: NCT03561220
Principal Investigator: Dr. Hartsell
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: Prostate Advanced Radiation Technologies Investigating Quality of Life: A Phase III Randomized Clinical Trial of Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer
Clinical Trial #: PARTIQoL
Principal Investigator: William Hartsell, MD
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: (IRONMAN) International Registry for Men with Advanced Prostate Cancer.
Clinical Trial #: c16-170
NCT Number: NCT03151629
Principal Investigator: Dr. George
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Low Risk Prostate Cancer

Study: Phase III prospective randomized trial of standard fractionation vs. hypofractionation with proton radiation therapy for low risk adenocarcinoma of the prostate.
Clinical Trial #: GU002-10
Principal Investigator: William Hartsell, MD
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Cervical

Study: Evaluation of Physical Function and Quality of Life (QOL) Before and After Non-Radical Surgical Therapy (Extra Facial Hysterectomy or Cone Biopsy with Pelvic Lymphadenectomy) for Stage IA1 (LVSI+) and IA2-IB1 (< 2CM) Cervical Cancer
Clinical Trial #: GOG0278
NCT Number: NCT01649089
Principal Investigator: Dr. Alter
Contact: Oncology Research Office 630.352.5360

Learn more at Clinicaltrials.gov


Endometrial

Study: A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women with Recurrent, Persistent or Metastatic Endometrial Cancer.: A Platform Trial for Women with Recurrent or Persistent Endometrial Cancer
Clinical Trial #: NRG-GY012
NCT #: NCT03660826
Principal Investigator: Dr. Alter
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Endometrial

Study: A Phase III Randomized Trial of Radiation +/- MK-3475 (Pembrolizumab) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
Clinical Trial #: GY020
NCT #: NCT04214067
Principal Investigator: Dr. Alter
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Endometrial

Study: A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Clinical Trial #: GY018
NCT #: NCT03914612
Principal Investigator: Dr. Alter
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Ovarian

Study: A Randomized Phase II Trial of Triplet Therapy (a PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination with Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women with Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
Clinical Trial #: NRG-GY023 / 22-013
NCT #: NCT04739800
Principal Investigator: Dr. Alter
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Ovarian

Study: A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]
Clinical Trial #: NRG-CC008
NCT #: NCT04251052
Principal Investigator: Dr. Alter
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Ovarian

Study: A Randomized phase II trial of radiation therapy and cisplatin alone or in combination with intravenous triapine in women with newly diagnosed bulky stage IB2, or stage II, IIIB, or IVA cancer of the uterine cervix or stage II-IVA vaginal cancer
Clinical Trial #: NRG-GY006
Principal Investigator: Dr. Alter
Contact: Oncology Research Office 630.352.5360

Learn more at Clinicaltrials.gov


Ovarian or Peritoneum

Study: A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Clinical Trial #: NRG-GY019
NCT Number: NCT04095364
Principal Investigator: Dr. Alter
Contact: Oncology Research Office 630.352.5360

Learn more at Clinicaltrials.gov

Current Northwestern Medicine Proton Center Clinical Trials

If you are interested in learning more about our trials, please contact your physician or visit the proton center website. If you are eligible for a proton therapy clinical trial as a patient at the Proton Center, someone from our team will likely reach out to you to communicate the details of the study.